United States Pain Management Therapeutics Market and Forecast Therapeutics (Pharmaceuticals and Devices), Drug Class, Indication, Pain Type, Distribution Channel and Company Analysis 2024-2032

Driving Forces for Pain Management Therapeutics in the United States

An increasing proportion of individuals experiencing persistent illness

The market is expanding primarily due to the rising prevalence of chronic illnesses such diabetes, cancer, heart disease, and arthritis, which necessitate the use of devices and painkillers. The growing use of painkillers to enhance patients' quality of life is also contributing to the expansion of the industry. In addition, the global aging population is driving up the number of older persons, who are more vulnerable to long-term conditions including osteoarthritis and neuropathic pain. 

For instance, the American Cancer Society reported in 2022 that there were 1.9 million new cases of cancer diagnosed in the United States. Furthermore, it is projected that the growing incidence of neurological disorders, such as brain tumors, will support market growth. A 2022 American Cancer Society Journal article estimates that 83,750 people in the US received a diagnosis of brain and other central nervous system cancer in 2021.

Additionally, the market is growing at the height of lifestyle changes that are raising risk factors, including obesity and physical inactivity. Moreover, a multimodal approach to pain management is becoming necessary due to the growing complexity of pain in chronic disorders, which is driving market expansion.

Pain treatment technologies are developing quickly

A favorable vision for the market's growth is being created by the quick technological developments in pain treatment, which have created new and more potent medications, such as biologics and targeted therapies. Accordingly, the market is growing because of the increasing advancements in the effectiveness of treatments to lessen the adverse effects of conventional painkillers. The pharmaceutical industry's increasing emphasis on research and development (R&D) for drugs and devices also contributes to the launch of medications with improved pain management profiles, improving the market's growth prospects. The market is expected to rise due to the growing acceptance of pharmacogenomics and customized medicine, which allow for more focused and efficient pain management techniques.

Increasing regulatory and governmental support

A favorable prognosis for the market's expansion is being created by implementing numerous government initiatives and regulations that encourage the creation and approval of innovative pharmaceuticals. Therefore, introducing incentives and fast-track approvals for orphan drug and device development is projected to propel market expansion by incentivizing pharmaceutical companies to invest in novel pain management treatments. The introduction of government-funded healthcare initiatives and reimbursement guidelines, which directly impact the availability and cost of painkillers, is also contributing significantly to the market's expansion in the United States. Furthermore, the market is enlarging owing to the increasing number of initiatives being established to improve access to painkillers in underprivileged areas, acknowledging pain treatment as a crucial aspect of public health.

California Pain Management Therapeutics Market

The dynamic field of pain management in California is centered on using a range of therapeutic and medical methods to control and reduce pain. It includes various services offered by medical specialists such as pharmacists, physiotherapists, psychiatrists, and pain management doctors. Multidisciplinary approaches to pain management, incorporating cutting-edge treatments like minimally invasive surgeries, nerve blocks, physical therapy, and non-opioid drugs, are a defining feature of the California market.

Due to the state's vast population and varied demographics, there is a high need for efficient pain management treatments due to ailments ranging from chronic pain to recovery following surgery. The market also shows continued initiatives to improve patient education and promote alternative pain management techniques in the fight against opioid abuse. Californian providers work collaboratively with technology businesses and research organizations to enhance treatment alternatives, giving patients comprehensive, individualized care customized to their requirements and circumstances.

United States Pain Management Therapeutics Company Analysis

The top Pain Management companies in the United States are Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories, Johnson & Johnson, and Baxter International Inc.

United States Pain Management Therapeutics Company News

October 2022 - Expanding its line of analgesics, Parker Laboratories Inc. develops, produces, and markets ultrasound and electromedical contact media, institutional cleansers, and disinfectants. The HelixTM line of products from the company now includes Tri-Active Therapy Cream, CBD Clinical Cream, and Helix CBD Therapy Cream.

September 2022 - A strategic alliance has been established by St. Louis-based private equity firm Compass Group Equity Partners and Memphis-based interventional pain treatment company Mays & Schnapp Neurospine and Pain ("Mays & Schnapp"). Compass Group Equity Partners serves patients in Tennessee and Mississippi.

January 2021— Boston Scientific Corporation introduced the WaveWriter Alpha line of spinal cord stimulator (SCS) devices, which combines therapeutic choices for individualized pain alleviation.

Therapeutics – Market breakup in 2 viewpoints:

1. Pharmaceuticals
2. Devices

2.1 Electrical Stimulators

2.2 Radiofrequency Ablation

2.3 Analgesic Infusion Pumps

2.4 Neurostimulation

Drug Class– Market breakup in 7 viewpoints:

1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2. Anesthetics
3. Anticonvulsants
4. Anti-Migraine Agents
5. Antidepressants
6. Opioids
7. Non-Narcotic Analgesics

Indication– Market breakup in 11 viewpoints:

1. Arthritic Pain
2. Neuropathic Pain
3. Cancer Pain
4. Chronic Back Pain
5. Post-Operative Pain
6. Migraine
7. Fibromyalgia
8. Bone Fracture
9. Muscle Sprain/Strain
10. Acute Appendicitis
11. Others

Pain Type – Market breakup in 2 viewpoints:

1. Chronic Pain
2. Acute Pain

Distribution Channel - Market breakup in 3 viewpoints:

1. Hospital Pharmacies
2. Retail Pharmacies
3. Online Pharmacies

All the key players have been covered from 4 Viewpoints:

• Business Overview
• Product Portfolio
• Recent Development & Strategies
• Revenue Analysis

Key Players Analysis:

1. Eli Lilly and Company

2. Pfizer Inc.

3. GlaxoSmithKline plc

4. Novartis International AG

5. Merck & Co., Inc.

6. Abbott Laboratories

7. Johnson & Johnson

8. Baxter International Inc.

Report Details: